CAR-T/CAR-NK Development

Expanding Immunotherapy Frontiers: Allogeneic CAR-T and CAR-NK Cells for Safer, Universal Cancer Treatment
Immunotherapy is transforming cancer treatment, with CAR-T cell therapy emerging as a groundbreaking approach for hematologic malignancies such as leukemia and lymphoma. To expand its therapeutic reach, researchers are developing allogeneic (off-the-shelf) CAR-T cells by disrupting genes like TCR to prevent graft-versus-host disease (GvHD).
In parallel, CAR-engineered natural killer (CAR-NK) cells are gaining momentum as an alternative platform. Unlike T cells, NK cells do not require prior activation and can recognize tumor cells independent of MHC expression—making them ideal for universal, allogeneic applications. CAR-NK therapies also tend to have a more favorable safety profile, with reduced risk of cytokine release syndrome (CRS) and neurotoxicity.
With deep expertise in tumor immunology, RedyBio provides comprehensive CRO services to accelerate your CAR-T, CAR-NK, and other immune cell therapy programs. Our services include:
- Monoclonal antibody development
- CAR construct design and vector production
- CAR lentivirus/Retrovirus manufacturing
- Immune cell isolation, activation, and transduction
- Phenotypic and functional analysis
- In vitro cytotoxicity assays
- In vivo efficacy models

RedyBio Custom Immune Cell Therapy Research Services
With deep expertise in tumor immunology, RedyBio provides comprehensive CRO services to accelerate your CAR-T, CAR-NK, and other immune cell therapy programs. Our services include:
Antibody Development
- Animal immunization
- Hybridoma generation and screening
- Subcloning and large-scale amplification
- Hybridoma sequencing
- Functional assay validation
CAR Design & Lentivirus Production
- Custom CAR molecule design and vector construction
- High-titer CAR lentiviral/retroviral vector production
- Stable cell line generation for target antigen expression
Immune Cell Preparation
- Human T and CAR-T cell preparation
- NK and CAR-NK cell generation
- Allogeneic (“universal”) CAR-T cell production
- Murine CAR-T cell services
Phenotypic Characterization
- T cell analysis: activation, exhaustion, memory subsets
- NK cell surface marker profiling
- Myeloid and other immune cell phenotyping
In Vitro Efficacy Assays
- CAR-T/NK cell proliferation assays
- Target cell cytotoxicity analysis
- Chronic antigen stimulation assay
- ADCC (antibody-dependent cellular cytotoxicity) assays
- ADCP (antibody-dependent cellular phagocytosis) assays
- Multiplex cytokine detection
In Vivo Efficacy Studies
- CDX (cell line-derived xenograft) tumor models using immunodeficient mice
- Syngeneic mouse tumor models
- Humanized immune system models (PBMC and HSC-based)
- Dosing studies and tumor growth monitoring
- Biochemical and histological analysis of tissues and samples
Contact us
- info@redybio.com
- (858) 876-8688
- 6331 Nancy Ridge Dr. Suite A San Diego, CA 92121
Let us work together
Reach out for more information or a quote. Our team is here to assist you with your research needs and inquiries.